Microsporidiosis : 400 mg orally twice a day for at least 3 weeks
Strongyloides : 400 mg orally twice a day for 3 days followed by a repeated dose after 3 weeks if necessary
Reversible increases in LFTs, leukopenia, pancytopenia, gastrointestinal disturbances (abdominal pain, nausea and vomiting), headache, dizziness, alopecia, rash, fever
Albendazole is an inducer of cytochrome P450 isoenzymes, leading to possible reduced blood levels of other drugs metabolized via this route e.g. warfarin, oral contraceptives, protease inhibitors, NNRTIs etc.
Dose as in normal renal function
Although there are no current recommendations for dose reduction in patients with moderate to severe hepatic dysfunction, since albendazole undergoes nearly 100% first-pass metabolism via the liver all patients with raised LFTS and receiving extended courses of albendazole should be monitored for leukopenia and pancytopenia
Limited Human Data – Animal Data Suggest Moderate Risk
Poor oral bioavailability. Take with fatty food to maximise oral absorption.
Unlicensed in UK, available from special order manufacturers.